tiprankstipranks
Advertisement
Advertisement
Aurinia Pharmaceuticals price target raised to $16 from $15 at RBC Capital
PremiumThe FlyAurinia Pharmaceuticals price target raised to $16 from $15 at RBC Capital
28d ago
Aurinia Posts Strong Q2 2026 Results on Rising LUPKYNIS Sales
Premium
Company Announcements
Aurinia Posts Strong Q2 2026 Results on Rising LUPKYNIS Sales
29d ago
Aurinia Posts Strong Q2 Results, Reaffirms 2026 Outlook and Advances Autoimmune Pipeline
Premium
Company Announcements
Aurinia Posts Strong Q2 Results, Reaffirms 2026 Outlook and Advances Autoimmune Pipeline
29d ago
Aurinia Pharmaceuticals announces initiation of PRESERVE study
PremiumThe FlyAurinia Pharmaceuticals announces initiation of PRESERVE study
2M ago
Aurinia’s PRESERVE Trial: New Combination Strategy for Lupus Nephritis in Focus
Premium
Company Announcements
Aurinia’s PRESERVE Trial: New Combination Strategy for Lupus Nephritis in Focus
3M ago
Aurinia Shareholders Back Board Slate and Governance Measures
Premium
Company Announcements
Aurinia Shareholders Back Board Slate and Governance Measures
3M ago
Aurinia Pharmaceuticals reports Q1 EPS 25c, consensus 20c
PremiumThe FlyAurinia Pharmaceuticals reports Q1 EPS 25c, consensus 20c
4M ago
Aurinia backs FY26 revenue view $315M-$325M, consensus $326.22M
Premium
The Fly
Aurinia backs FY26 revenue view $315M-$325M, consensus $326.22M
4M ago
Aurinia Pharmaceuticals to Acquire Kezar, Expanding Autoimmune Pipeline
Premium
Company Announcements
Aurinia Pharmaceuticals to Acquire Kezar, Expanding Autoimmune Pipeline
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100